Current status of intrathecal chemotherapy for human meningeal neoplasms.

Abstract

Progress in clinical intrathecal chemotherapy has been slow, and a number of new problems have been encountered. The most significant recent developments include the: 1) success of adjunctive intrathecal chemotherapy in the prevention of meningeal leukemia; 2) recognition and characterization of a necrotizing leukoencephalopathic reaction associated with intrathecal methotrexate therapy; 3) demonstration of the efficacy of intraventricular chemotherapy via an Ommaya reservoir; 4) delineation of the clinical pharmacology of intralumbar and intraventricular methotrexate; and 5) identification of an urgent need for new drugs and techniques for intrathecal administration.

• Authors: W A Bleyer
• Journal: National Cancer Institute monograph (Natl Cancer Inst Monogr) Vol. 46 Pg. 171-8 (Dec 1977) ISSN: 0083-1921 [Print] United States
• PMID: 580638 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Methotrexate

Topics

• Animals
• Antineoplastic Agents (administration & dosage)
• Arachnoiditis (chemically induced)
• Child
• Humans
• Injections, Intraventricular (methods)
• Injections, Spinal
• Leukemia (drug therapy)
• Leukoencephalopathy, Progressive Multifocal (chemically induced)
• Meningeal Neoplasms (cerebrospinal fluid, drug therapy)
• Methotrexate (administration & dosage, adverse effects, cerebrospinal fluid)
• Research Design